Project Grant HT94252510303
Award Date
6/15/25
Completion Date
6/14/27
Dollars Obligated
$671K
Federal Agency
Defense Health Agency
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Hamden, CT 06511, USA
Similar Awards
The federal Project Grant award, with ID HT94252510029, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The $460,279.00 award, which commenced on February 15, 2025, supports Yale University's research on "Loss of Proteostasis and Vascular Amyloidosis" over a 2-year period ending on February 14, 2027. The university's research aims to investigate innovative approaches to the prevention, diagnosis, treatment,...
The Defense Health Agency awarded Yale University a $3,129,087.00 Project Grant on September 1, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant supports advanced research to develop integrative platforms for cellular immunotherapies against resistant hematopoietic malignancies and solid tumors. Key aims include targeting combinations of gene editing and CAT inhibition to enhance CAR-T cell function, and investigating gene editing coupled with CAT...
This $859,773 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports research at Yale University on biomarkers and targets for leptomeningeal disease progression from non-small cell lung cancer (NSCLC) brain metastasis. The research aims to transform healthcare for military service members and the public by advancing innovative, impactful medical solutions. The award period runs from May 1,...
This $249,612 federal Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research led by Yale University to unravel the causal impact of multiple sclerosis (MS)-associated genetic variants on T cell immune tolerance. The project will be conducted over a 2-year period from September 1, 2025 to August 31, 2027, with the goal of advancing the scientific understanding of MS pathogenesis and...
The Defense Health Agency awarded Yale University a 3-year, USD 1,277,053 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to target the chromatin regulator WDR5 to treat breast cancer metastasis. The project aims to advance the understanding and development of novel therapeutic approaches for breast cancer, a leading cause of cancer-related deaths. As the prime awardee, Yale University will conduct the research, development, and testing activities...
This Project Grant award from the Defense Health Agency, through the Military Medical Research and Development program (CFDA 12.420), provides $514,335 to Yale University to optimize adoptive cellular immunotherapy for rare melanomas. The award began on September 1, 2023 and is scheduled for completion on August 31, 2026. The research aims to transform health care for service members and the American public through innovative and impactful medical solutions, with a focus on developing treatments...
This $201,000 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports research at Yale University to investigate the role of the RBM10 gene in the development of lung squamous cell carcinoma. The award, effective from March 1, 2025 to February 28, 2026, will enable Yale to conduct advanced biomedical research focused on transforming healthcare for military service members and the general public...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...
The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
The Defense Health Agency awarded Yale University a $837,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "MECHANISM-CENTRIC PREDICTIVE MODELING FOR PROSTATE CANCER". The 3-year grant, running from July 1, 2024 to June 30, 2027, supports Yale's work to develop new predictive modeling approaches for prostate cancer. This research aims to improve understanding of the underlying biological mechanisms driving prostate cancer...